Pharmaceutical Executive Daily: Amgen Acquires Dark Blue Therapeutics for $840 Million
In today’s Pharmaceutical Executive Daily, Amgen announces an $840 million acquisition of Dark Blue Therapeutics, GSK enters a multi-year precision medicine collaboration with Helix, and industry leaders examine how workable operating models are reshaping cell and gene therapy co ...Show more
Pharmaceutical Executive Daily: Alnylam Invests $250 Million in Manufacturing Facility
In today’s Pharmaceutical Executive Daily, Eli Lilly and Nimbus Therapeutics announce a major licensing deal for oral obesity treatments, Hoth Therapeutics expands its intellectual property portfolio with new provisional patents, and Alnylam commits $250 million to expand manufac ...Show more